130 related articles for article (PubMed ID: 2139303)
1. The cardiovascular and endocrine effects of cilazapril, a new angiotensin-converting enzyme inhibitor, in man.
Ajayi AA; Reid JL
Afr J Med Med Sci; 1990 Mar; 19(1):33-8. PubMed ID: 2139303
[TBL] [Abstract][Full Text] [Related]
2. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
Waterfall JF
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
[TBL] [Abstract][Full Text] [Related]
3. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
Ajayi AA; Elliott HL; Reid JL
Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
[TBL] [Abstract][Full Text] [Related]
4. Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.
Burnier M; Mooser V; Nussberger J; Waeber B; Brunner HR
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):189S-197S. PubMed ID: 2527532
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic converting enzyme inhibition on the vascular renin-angiotensin system.
Saito H; Nakamaru M; Rakugi H; Mikami H; Ogihara T; Inagami T
Clin Exp Pharmacol Physiol; 1990 Nov; 17(11):745-53. PubMed ID: 2150362
[TBL] [Abstract][Full Text] [Related]
6. The effect of acute ACE inhibition on atrial natriuretic peptide.
Doorenbos CJ; van Brummelen P
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):243S-247S. PubMed ID: 2527537
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effects of renin inhibition and angiotensin converting enzyme inhibition upon bradykinin potentiation.
Véniant M; Clozel JP; Fischli W
J Hypertens; 1992 Feb; 10(2):155-60. PubMed ID: 1313478
[TBL] [Abstract][Full Text] [Related]
8. The 24 h blood pressure responses of hypertensives to a once-a-day cilazapril regimen.
Fernandez PG; Bolli P; Lee C
Can J Cardiol; 1990 Mar; 6(2):53-8. PubMed ID: 2138051
[TBL] [Abstract][Full Text] [Related]
9. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.
Belz GG; Essig J; Kleinbloesem CH; Hoogkamer JF; Wiegand UW; Wellstein A
Br J Clin Pharmacol; 1988 Nov; 26(5):547-56. PubMed ID: 2974715
[TBL] [Abstract][Full Text] [Related]
10. The effects of cilazapril alone and in combination with frusemide in healthy subjects.
Johnston GD; Passmore AP
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):235S-242S. PubMed ID: 2527536
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular pressor reactivity after chronic converting enzyme inhibition.
Bernasconi M; Marone C; Beretta-Piccoli C; Lepori G; Shaw S; Weidmann P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):348-55. PubMed ID: 1829371
[TBL] [Abstract][Full Text] [Related]
12. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
Gasic S; Heinz G; Kleinbloesem C; Korn A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):225S-234S. PubMed ID: 2548552
[TBL] [Abstract][Full Text] [Related]
13. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
Nussberger J; Fasanella d'Amore T; Porchet M; Waeber B; Brunner DB; Brunner HR; Kler L; Brown AN; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):39-44. PubMed ID: 2434792
[TBL] [Abstract][Full Text] [Related]
14. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril.
Massarella JW; DeFeo TM; Brown AN; Lin A; Wills RJ
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):205S-209S. PubMed ID: 2527534
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics and dose proportionality of cilazapril.
Massarella J; DeFeo T; Lin A; Limjuco R; Brown A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):199S-204S. PubMed ID: 2527533
[TBL] [Abstract][Full Text] [Related]
16. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
Fasanella d'Amore T; Bussien JP; Nussberger J; Waeber B; Turini GA; Brunner HR; Kler L; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):26-31. PubMed ID: 2434790
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers.
Anderson PJ; Critchley JA; Tomlinson B
Eur J Clin Pharmacol; 1996; 50(1-2):57-62. PubMed ID: 8739812
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
[TBL] [Abstract][Full Text] [Related]
19. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
Erb KA; Breithaupt K; Kleinbloesem CH; Wolf GK; Belz GG
Clin Physiol Biochem; 1990; 8 Suppl 2():35-45. PubMed ID: 2151315
[TBL] [Abstract][Full Text] [Related]
20. Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.
Rosendorff C; Patton J; Radford HM; Kalliatakis B
J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S105-9. PubMed ID: 1382157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
